IDF23-0498 Subgroup analysis of Phase 3 study of dapagliflozin, glimepiride and metformin ER FDC in T2DM patients with HbA1c 9% –11%
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: R. Sahay, D. Gangwani, M. Singh, S. Gupta, M. Rajurkar, S. Saha, D. Patil, P. Ghadge, L. Lakhwani, S. Mehta, S. Joglekar Tags: Diabetes in Crises: Natural Disasters and Conflict Source Type: research
More News: Dapagliflozin | Diabetes | Endocrinology | Fortamet | Forxiga | Glimepiride | Metformin | Study